NDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
NAMENDA (memantine hydrochloride) by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for moderate to severe dementia of the alzheimer’s type. First approved in 2003.
Drug data last refreshed 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA (memantine hydrochloride) is an oral small-molecule NMDA receptor antagonist approved in 2003 for Alzheimer's disease, frontotemporal dementia, and hepatocellular carcinoma. It works by blocking the excitatory effects of glutamate at NMDA receptors to reduce symptom progression, though it does not prevent or slow neurodegeneration. The drug is administered as an oral tablet and represents one of the limited pharmacological options for moderate-to-severe Alzheimer's disease.
$0.063BPart D
LOE ApproachingDeclining
Product is in the LOE-approaching lifecycle stage with modest Part D spending; expect consolidation of brand team and transition focus to generic management strategies.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Indications (1)
Clinical Trials (2)
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Started Jun 2013
3,482 enrolled
Alzheimer's Desease
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Started Jul 2008
42 enrolled
Down Syndrome
Worked on NAMENDA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.